Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M5717 plus Pyronaridine in Acute Uncomplicated Plasmodium Falciparum Malaria
NCT05689047Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Mar 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of cabamiquine in Plasmodium falciparum malaria (2 arms), sponsored by Merck KGaA. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events, Clinically Significant Change From Baseline in Safety Laboratory Parameters and 3 more. Started Mar 2023; status: completed.
02
Drugs
cabamiquine
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT05689047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05689047.